MRC sells Keytruda royalty rights for $150M

MRC Technology (London, U.K.) sold a portion of its royalty rights to PD-1 inhibitor Keytruda pembrolizumab to DRI Capital for $150 million. Merck & Co. Inc. (NYSE:MRK) markets Keytruda to treat melanoma and non-small cell lung cancer (NSCLC).

MRC Technology spokesperson Liezel Tipper said the not-for-profit sold a "percentage of future royalties until a pre-agreed aggregate fixed cap of royalties is achieved." She said the exact percentage depends on future Keytruda sales...